Suchergebnisse - "Koenig, Erica"

PubPharm (7)

1

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping : A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial

enthalten in: Nucleic acid therapeutics | 2022

von Servais, L. | Mercuri, E. | Straub, V. | +29

2

Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping : A randomized, double-blind, placebo-controlled, dose-titration trial

enthalten in: Muscle & nerve | 2021

von Wagner, K. | Kuntz, N. | Koenig, E. | +4

3

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping : PROMOVI Trial

enthalten in: Journal of neuromuscular diseases | 2021

von McDonald, C. | Shieh, P. | Abdel-Hamid, H. | +12

4

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

enthalten in: Acta neuropathologica communications | 2021

von Scaglioni, D. | Catapano, F. | Ellis, M. | +17

5

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

enthalten in: Acta Neuropathologica Communications | 2021

von Scaglioni, D. | Catapano, F. | Ellis, M. | +17

6

Safety, tolerability, and pharmacokinetics of casimersen in patients with D uchenne muscular dystrophy amenable to exon45 skipping : A randomized, double‐blind, placebo‐controlled, dose‐titration trial

enthalten in: Muscle & Nerve | 2021

von Wagner, K. | Kuntz, N. | Koenig, E. | +4

7

Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054

enthalten in: Movement disorders : official journal of the Movement Disorder Society | 2019

von Brys, M. | Fanning, L. | Hung, S. | +15

1
[1]